Stroke outcomes, recovery correlate with MMP-9 levels

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Serum levels of matrix metalloprotease 9 (MMP-9) are associated with stroke outcomes and clinical improvement.

Why this matters

  • MMP-9 levels are known to increase after cerebral ischemia and may modulate complications associated with tissue plasminogen activator (TPA) therapy.

Key results

  • MMP-9 levels at admission were associated with 1-mo outcomes by modified Rankin Scale (mRS) score (P=.001).
  • MMP-9 levels at 1 mo were associated with National Institutes of Health Stroke Scale (NIHSS) score and mRS score at 1 mo (P=.004 and P=.001, respectively).
  • MMR-9 levels at 1 mo were associated with NIHSS score and mRS score at onset (P=.002 and P=.001, respectively).
  • MMP-9 levels at 1 mo were associated with clinical improvement (difference between NIHSS score at onset and 1 mo, P=.022).

Study design

  • 30 patients with acute ischemic stroke and 30 controls patients were analyzed for associations between MMP-9 and stroke severity, outcomes, and clinical recovery.
  • Funding: None disclosed.

Limitations

  • Small patient sample size.